Novo Nordisk has introduced its weight-loss drug, Wegovy, in India. This launch follows Eli Lilly's entry into the market.

While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

Beyond current successes, Eli Lilly is innovating with a potential game-changing oral GLP-1, orforglipron. Read why I ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

Amgen's late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls its ...

Hims & Hers ( HIMS) stock plummeted around 30% in early trading Monday after Novo Nordisk ( NVO) announced it was ending a ...

Stocks rose Monday, with oil prices declining, following a restrained response by Iran to U.S. attacks over the weekend.

The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...

While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, ...

Novo Nordisk (NVO) and Hims and Hers Health (HIMS) shares are sinking on an ended partnership, with the former also ...

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

Novo Nordisk ends partnership with Hims & Hers over safety and marketing concerns tied to compounded Wegovy, as rivalry with ...